Daiichi Sankyo Stock Price, News & Analysis (OTCMKTS:DSNKY) $26.93 -0.08 (-0.30%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$26.63▼$27.1050-Day Range$23.74▼$29.0352-Week Range$23.72▼$37.57Volume152,370 shsAverage Volume146,625 shsMarket CapitalizationN/AP/E Ratio0.23Dividend Yield83.43%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Daiichi Sankyo MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthyDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Daiichi Sankyo. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently decreased by 30.80%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldDaiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDaiichi Sankyo does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSNKY. Previous Next 2.7 News and Social Media Coverage News SentimentDaiichi Sankyo has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Daiichi Sankyo this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Daiichi Sankyo is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Daiichi Sankyo is 0.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Daiichi Sankyo is 0.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.85. Previous Next See Top Rated MarketRank™ Stocks Here About Daiichi Sankyo Stock (OTCMKTS:DSNKY)Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More DSNKY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSNKY Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comJapan panel recommends approval of updated Daiichi Sankyo COVID shot- KyodoNovember 21, 2023 | americanbankingnews.comDaiichi Sankyo (OTCMKTS:DSNKY) and Gilead Sciences (NASDAQ:GILD) Head to Head AnalysisNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 31, 2023 | investing.comDaiichi Sankyo Co., Ltd. (4568)October 31, 2023 | finance.yahoo.comMerck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?October 26, 2023 | finance.yahoo.comMerck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts SalesOctober 26, 2023 | finance.yahoo.com‘Guided Missile Drugs’ Could Be Big Pharma’s Secret WeaponOctober 23, 2023 | bloomberg.comMerck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo DealNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 22, 2023 | finance.yahoo.comRaludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early TrialOctober 20, 2023 | finance.yahoo.comNikkei Falls 0.5%, Dragged by Electronics, Retail StocksOctober 20, 2023 | barrons.comJapan's Daiichi Sankyo, Merck Announce $22bn Cancer Drug DealOctober 20, 2023 | news.yahoo.comMerck teams up with Daiichi Sankyo on antibody drug conjugate collaborationOctober 20, 2023 | reuters.comMerck signs $5.5 bln deal with Daiichi for cancer therapy developmentOctober 18, 2023 | finance.yahoo.comExperimental Drug Wards Off Both Lung and Breast Cancer Progression in TrialsOctober 16, 2023 | finance.yahoo.comDaiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMOSeptember 26, 2023 | finance.yahoo.comNikkei Falls 1.1%, Dragged by Pharma, Electronics StocksSeptember 25, 2023 | finance.yahoo.comU.S. Stocks Open Lower After S&P 500 Logs Three Straight Weeks Of LossesSeptember 25, 2023 | finance.yahoo.comDaiichi Sankyo Leads Japan Pharma Stocks Higher on Cancer DrugSeptember 25, 2023 | finance.yahoo.comStock Market Today: Bond Yields Climb Toward 4.5%September 24, 2023 | finance.yahoo.comNikkei Flat, Supported by Electronics, Pharma StocksSeptember 22, 2023 | finance.yahoo.comDatopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 TrialSeptember 22, 2023 | finance.yahoo.comAstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops ChemoSeptember 15, 2023 | lse.co.ukAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvalSeptember 15, 2023 | finance.yahoo.comUPDATE 1-EU regulator backs AstraZeneca and Daiichi's lung cancer drugSeptember 12, 2023 | bloomberg.comDaiichi to File for US Approval of New Lung Cancer Drug by MarchSeptember 10, 2023 | finance.yahoo.comPatritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 TrialSee More Headlines Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - General Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:DSNKY CUSIPN/A CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.23 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Sunao Manabe D.V.M. (Age 69)Ph.D., Group CEO & Executive Chairperson Comp: $1.87MMr. Hiroyuki Okuzawa (Age 61)President, COO & Representative Director Comp: $735.57kMr. Masahiko Ohtsuki (Age 64)Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director Comp: $735.57kDr. Shoji Hirashima (Age 62)Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director Comp: $795.75kMr. Koji OgawaManaging Executive Officer, Head of Global Corporate Planning & Management and CFOHiroto KashiwaseManaging Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQNaoto TsukaguchiGen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.Kentaro AsakuraVice President of Corporate Communications DepartmentMs. Marielle Cohard-Radice M.D.Global Head of DevelopmentAkio SakuraiCorporate Officer, Head of Sales and Marketing Div. & Japan Business UnitMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFView All Competitors DSNKY Stock Analysis - Frequently Asked Questions Should I buy or sell Daiichi Sankyo stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" DSNKY shares. View DSNKY analyst ratings or view top-rated stocks. How have DSNKY shares performed in 2023? Daiichi Sankyo's stock was trading at $32.19 at the beginning of 2023. Since then, DSNKY stock has decreased by 16.3% and is now trading at $26.93. View the best growth stocks for 2023 here. Are investors shorting Daiichi Sankyo? Daiichi Sankyo saw a decrease in short interest in November. As of November 15th, there was short interest totaling 35,500 shares, a decrease of 30.8% from the October 31st total of 51,300 shares. Based on an average daily volume of 166,300 shares, the days-to-cover ratio is presently 0.2 days. View Daiichi Sankyo's Short Interest. Is Daiichi Sankyo a good dividend stock? Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:DSNKY) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.